AEON Biopharma, Inc. business relationships
Companies named in AEON Biopharma, Inc.’s 10-K filed 2026-03-30, and public companies whose annual reports name AEON Biopharma, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.6 / 10
- AI naming
- 4 / 100 Top 12% in its category
- Agent readiness
- 25 / 100
- AI adoption
- 0 / 100
Named in AEON Biopharma, Inc.’s annual report 2
“...ived approval for, its injectable botulinum toxin, daxibotulinumtoxinA, for the therapeutic indications of cervical dystonia and adult upper limb spasticity, and which has also entered into a collaboration and license agreement with Viatris Inc. to develop and commercialize a biosimilar to Botox®. |” SEC filing
“In the event ABP-450 receives regulatory approval, we and our direct and indirect suppliers, including Daewoong, will remain subject to the periodic inspection of our plants and facilities, review of production processes, and testing of our products to confirm that we are in compliance with all appl...” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.